The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

The Effect of a Thiazolidinedione Drug, Troglitazone, on Glycemia in Patients with Type 2 Diabetes Mellitus Poorly Controlled with Sulfonylurea and Metformin: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Jean-François Yale, MD; Thomas R. Valiquett, MS; Mahmoud N. Ghazzi, MD, PhD; Janet K. Owens-Grillo, PhD; Randall W. Whitcomb, MD; Howard L. Foyt, MD, PhD, Troglitazone Triple-Therapy Study Group*
[+] Article, Author, and Disclosure Information

From McGill University, Montreal, Quebec, Canada; and Parke-Davis Pharmaceutical Research, Ann Arbor, Michigan.

Note: Portions of these data were present at the 59th Annual Meeting of the American Diabetes Association, June 1999.

Acknowledgments: The authors thank Miggi Tomovici, Nadia Romano, Daniel Strieter, Sandra Vermeulen, and Barbara Faja for their assistance with summarizing data.

Grant Support: By Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company.

Requests for Single Reprints: Jean-François Yale, MD, McGill University Health Centre, 687 Pine Avenue West, Room H685, Montreal, Quebec H3A 1A1, Canada.

Current Author Addresses: Dr. Yale: McGill University Health Centre, 687 Pine Avenue West, Room H685, Montreal, Quebec H3A 1A1, Canada.

Mr. Valiquett and Drs. Ghazzi, Owens-Grillo, Whitcomb, and Foyt: Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105.

Author Contributions: Conception and design: J.F. Yale, T.R. Valiquett, M.N. Ghazzi, R.W. Whitcomb, H.L. Foyt.

Analysis and interpretation of the data: J.F. Yale, T.R. Valiquett, J.K. Owens-Grillo, R.W. Whitcomb, H.L. Foyt.

Drafting of the article: J.F. Yale, T.R. Valiquett.

Critical revision of the article for important intellectual content: T.R. Valiquett, J.K. Owens-Grillo, R.W. Whitcomb, H.L. Foyt.

Final approval of the article: J.F. Yale, R.W. Whitcomb, H.L. Foyt.

Provision of study materials or patients: J.F. Yale.

Administrative, technical, or logistic support: J.K. Owens-Grillo.

Collection and assembly of data: T.R. Valiquett, J.K. Owens-Grillo.

Ann Intern Med. 2001;134(9_Part_1):737-745. doi:10.7326/0003-4819-134-9_Part_1-200105010-00010
Text Size: A A A

Persistent hyperglycemia secondary to insulin resistance and eventual insufficient insulin secretory capacity is the hallmark of type 2 diabetes mellitus. Resistance to insulin-stimulated glucose uptake is present in most patients with this disease (1). Treatment is aimed at reducing blood glucose levels to normal or near-normal values (23). Diet and exercise are the first treatments of choice for patients with type 2 diabetes mellitus. However, as many as 95% of those with newly diagnosed diabetes do not achieve adequate blood glucose control after a 3-month dietary intervention (4), and initiation with oral antidiabetes therapy is then advocated.

First Page Preview

View Large
First page PDF preview


Grahic Jump Location
Figure 1. ALT = alanine aminotransferase.
Random assignment and disposition of patients.
Grahic Jump Location
Grahic Jump Location
Figure 2. The troglitazone/troglitazone group ( ) was treated with troglitazone, 400 mg/d, for the entire 48 weeks; the placebo/troglitazone group ( ) was treated with a placebo for the first 24 weeks and with troglitazone, 400 mg/d, for the last 24 weeks. Data are presented as the mean ± SE. Change in fasting glucose level from baseline to 24 weeks (double-blind period) and from 24 to 48 weeks (open-label period). To convert glucose values in mmol/L to mg/dL, multiply by 18.0. Change in hemoglobin A level over time. To convert hemoglobin values to percentages, multiply by 100.
Changes in fasting glucose and hemoglobin A 1c levels from baseline to 6 and 12 months.dotted linessolid linesTop.Bottom.1c
Grahic Jump Location




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Triple-Drug Therapy May Improve Sugar Control in Adults with Diabetes

The summary below is from the full report titled “The Effect of a Thiazolidinedione Drug, Troglitazone, on Glycemia in Patients with Type 2 Diabetes Mellitus Poorly Controlled with Sulfonylurea and Metformin. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.” It is in the 1 May 2001 issue of Annals of Internal Medicine (volume 134, pages 737-745). The authors are JF Yale, TR Valiquett, MN Ghazzi, JK Owens-Grillo, RW Whitcomb, and HL Foyt, for the Troglitazone Triple-Therapy Study Group.


Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $32.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.